These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32272489)

  • 1. Correlation Between Bevacizumab Exposure and Survival in Patients with Metastatic Colorectal Cancer.
    Papachristos A; Kemos P; Kalofonos H; Sivolapenko G
    Oncologist; 2020 Oct; 25(10):853-858. PubMed ID: 32272489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bevacizumab Treatment for Metastatic Colorectal Cancer in Real-World Clinical Practice.
    Dinu IM; Mihăilă M; Diculescu MM; Croitoru VM; Turcu-Stiolica A; Bogdan D; Miron MI; Lungulescu CV; Alexandrescu ST; Dumitrașcu T; Buică F; Luca IN; Lungulescu C; Negulescu MC; Gramaticu IM; Cazacu IM; Croitoru AE
    Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837551
    [No Abstract]   [Full Text] [Related]  

  • 3. Primary tumor location and bevacizumab effectiveness in patients with metastatic colorectal cancer.
    Boisen MK; Johansen JS; Dehlendorff C; Larsen JS; Østerlind K; Hansen J; Nielsen SE; Pfeiffer P; Tarpgaard LS; Holländer NH; Keldsen N; Hansen TF; Jensen BB; Jensen BV
    Ann Oncol; 2013 Oct; 24(10):2554-2559. PubMed ID: 23864097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. aCGH Analysis of Predictive Biomarkers for Response to Bevacizumab plus Oxaliplatin- or Irinotecan-Based Chemotherapy in Patients with Metastatic Colorectal Cancer.
    Fujita Y; Taguri M; Yamazaki K; Tsurutani J; Sakai K; Tsushima T; Nagase M; Tamagawa H; Ueda S; Tamura T; Tsuji Y; Murata K; Taira K; Denda T; Moriwaki T; Funai S; Nakajima TE; Muro K; Tsuji A; Yoshida M; Suyama K; Kurimoto T; Sugimoto N; Baba E; Seki N; Sato M; Shimura T; Boku N; Hyodo I; Yamanaka T; Nishio K
    Oncologist; 2019 Mar; 24(3):327-337. PubMed ID: 30425180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of Combining Bevacizumab With First-Line Chemotherapy Regimens for Metastatic Colorectal Cancer in Real-World Practice.
    Bang YH; Hong YS; Lee JS; Lee KW; Han HS; Kim SY; Kim JW; Kim HK; Kim JW; Eun CK; Kim TW; Kim JE
    Clin Colorectal Cancer; 2021 Jun; 20(2):101-112.e6. PubMed ID: 33223477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High serum proteinase-3 levels predict poor progression-free survival and lower efficacy of bevacizumab in metastatic colorectal cancer.
    Furuya K; Nakajima M; Tsunedomi R; Nakagami Y; Xu M; Matsui H; Tokumitsu Y; Shindo Y; Watanabe Y; Tomochika S; Maeda N; Iida M; Suzuki N; Takeda S; Hazama S; Ioka T; Hoshii Y; Ueno T; Nagano H
    BMC Cancer; 2024 Feb; 24(1):165. PubMed ID: 38308214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor calcification is associated with better survival in metastatic colorectal cancer patients treated with bevacizumab plus chemotherapy.
    Zhou YW; Long YX; Liu X; Liu JY; Qiu M
    Future Oncol; 2022 Jul; 18(22):2453-2464. PubMed ID: 35712899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of primary tumour location, early tumour shrinkage, and depth of response in the treatment of metastatic colorectal cancer with first-line chemotherapy plus cetuximab or bevacizumab.
    Sagawa T; Sato Y; Hirakawa M; Hamaguchi K; Fukuya A; Okamoto K; Miyamoto H; Muguruma N; Fujikawa K; Takahashi Y; Takayama T
    Sci Rep; 2020 Nov; 10(1):19815. PubMed ID: 33188279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
    Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
    Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer.
    Hurwitz HI; Yi J; Ince W; Novotny WF; Rosen O
    Oncologist; 2009 Jan; 14(1):22-8. PubMed ID: 19144677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Evaluation of bevacizumab combined with irinotecan-based regimen as the first-line treatment for patients with metastatic colorectal cancer].
    Lin L; Xu JM; Wang Y; Ge FJ; Liu LJ; Zhao CH; Li SS; Liu JZ; Li ZQ
    Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):786-90. PubMed ID: 21163073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
    Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
    Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer.
    Degirmenci M; Karaca B; Gorumlu G; Durusoy R; Demir Piskin G; Bozkurt MT; Cirak Y; Tunali D; Karabulut B; Sanli UA; Uslu R
    Med Oncol; 2010 Sep; 27(3):585-91. PubMed ID: 19526201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
    Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
    Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line therapy of bevacizumab plus chemotherapy versus cetuximab plus chemotherapy for metastatic colorectal cancer patients with mucinous adenocarcinoma or mucinous component.
    Zhou YW; Long YX; Chen Y; Liu JY; Pu D; Huang JY; Bi F; Li Q; Gou HF; Qiu M
    Cancer Med; 2021 May; 10(10):3388-3402. PubMed ID: 33939281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.
    Fujii H; Matsuhashi N; Kitahora M; Takahashi T; Hirose C; Iihara H; Yamada Y; Watanabe D; Ishihara T; Suzuki A; Yoshida K
    Oncologist; 2020 Mar; 25(3):e469-e476. PubMed ID: 32162797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of time-varying cumulative bevacizumab exposures on survival: re-analysis of data from randomized clinical trial in patients with metastatic colo-rectal cancer.
    Guilloteau A; Abrahamowicz M; Boussari O; Jooste V; Aparicio T; Quantin C; Le Malicot K; Binquet C
    BMC Med Res Methodol; 2021 Jan; 21(1):14. PubMed ID: 33422006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confounding mitigation for the exposure-response relationship of bevacizumab in colorectal cancer patients.
    Lobet S; Caulet M; Paintaud G; Azzopardi N; Desvignes C; Chautard R; Borg C; Capitain O; Ferru A; Bouché O; Lecomte T; Ternant D
    Br J Clin Pharmacol; 2024 Apr; 90(4):976-986. PubMed ID: 38072829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.